Today: 19 July 2026
Browse Category

NASDAQ:ACLX 9 December 2025 - 25 February 2026

Arcellx (ACLX) Stock Surges on Anito-cel Breakthrough Data as Analysts Boost Price Targets – December 9, 2025

Arcellx (ACLX) Stock Surges on Anito-cel Breakthrough Data as Analysts Boost Price Targets – December 9, 2025

Arcellx, Inc. has jumped back onto Wall Street’s radar after releasing highly positive Phase 2 data for its multiple myeloma cell therapy anitocabtagene autoleucel at the American Society of Hematology 2025 meeting. The new data have driven a sharp move in the stock, a flurry of analyst updates, and renewed debate about valuation ahead of a planned 2026 commercial launch.
Go toTop